News

Derek Kunimoto, MD, JD, focuses on Aviceda's technology, which will aim to target various immune system responses that contribute to pathology associated with dry AMD.

ASRS 2020: Josh Anderson speaks on the highlights from Alcon, including new data on the performance benefits of the Hypervit dual blade 20,000 cpm probe and the launch of the NGENUITY 1.4 upgrade.

PDS with ranibizumab is proving to be an innovation solution for nAMD patients. Peter Campochiaro, MD, detailed findings of phase 2 of the Ladder Trial and ongoing Archway Trial during the virtual 2020 ASRS annual meeting.

The results of the Protocol T Extension Study underscore the need for methods to improve long-term visual gains in eyes with diabetic macular edema, according to Dante Pieramici, MD, on behalf of the DRCR Retina Network, during the American Society of Retina Specialists 2020 Virtual Annual Meeting.

Carl Danzig, MD, presented results of phase 2 Stairway Trial during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.

An augmented-reality device provides AMD patients with enhanced reading ability and facial recognition.

Intravitreal liposome-encapsulated bromfenac is under study as a treatment for refractory DME. Results of a pilot study were detailed at the virtual 2020 ASRS annual meeting.

The Audacious Goals Initiative of the National Eye Institute is focused on developing noninvasive imaging advances to help patients with vision loss.

These imaging technologies can help with assessing unexpected structural and vascular retinal and choroidal changes in active and post-treatment toxoplasmic retinochoroiditis.

A study of adult patients with diabetes found that bowtie-shaped polarization artifacts do not serve as reliable clinical biomarkers for center-involving diabetic macular edema. What might this mean for clinicians?

An in-office intravitreal therapy delivering a gene for aflibercept expression continues to demonstrate encouraging safety, tolerability, and efficacy in a phase 1 study of patients with neovascular age-related macular degeneration who require frequent injections to control their disease.

Treatment with a single ocriplasmin injection led to clinically meaningful improvements in the patient-reported visual function measured by the VFQ-25 questionnaire over 24 months in patients with symptomatic vitreomacular adhesion.

Only 2% of patients with internal limiting membrane peeling developed an epiretinal membrane compared with 46% with no peeling.

Fundus autofluorescence is a helpful tool for diagnosing central serous choroidopathy and planning treatment.

Immediate administration after radiation therapy is key.

Physicians can discover, diagnose, document, treat diseases that might go undetected

Patient enrollment for the NORSE 2 clinical trial has been completed, with safety and efficacy data expected to be reported in the third quarter of 2021.

Chronic cases can be difficult for retina specialists; treatment is satisfying.

Use of anxiety-screening questionnaires in patients needing intravitreal anti-VEGF injections may help to identify individuals at risk for elevated pain during the procedure, according to research presented at ARVO 2020.

A large case-control study found that among adults aged 55 years and older, the use of metformin significantly decreased the risk of being newly diagnosed with age-related macular degeneration within 2 years.

An analysis using a large commercial claims database found that almost 3% of patients developed severe diabetic eye disease within 5 years of being diagnosed with type 2 diabetes. Clinical and demographic risk factors were also identified.

A new analysis from the DRCR Network Protocol V showed that many patients with center-involved diabetic macular edema and good vision do not require treatment for visual acuity loss.

Face-down positioning is associated with a reduction in certain complications following macula-involving retinal displacement (RD) repair, according to researchers.

This study provided clinical proof of concept for viral vector-mediated gene supplementation therapy of inherited day blindness caused by pathogenic variants in the cone photoreceptor-specific gene CNGA3.

Used as an adjunct, ST laser therapy may reduce the treatment burden for patients while maintaining visual acuity.